Status:
TERMINATED
Investigating the Anti-Human Immunodeficiency Virus (HIV) & Anti-inflammatory Effect of Chloroquine
Lead Sponsor:
University of Minnesota
Collaborating Sponsors:
Minnesota Medical Foundation
Conditions:
HIV Infections
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
PHASE3
Brief Summary
Summary: Chloroquine is a medication that in laboratory settings has significant anti-HIV effects in HIV infected T-cells. Chloroquine has been used safely for over 60 years for malaria treatment and ...
Detailed Description
Summary: A phase I randomized, double-blind, placebo controlled trial to investigate the efficacy of chloroquine to decrease T-cell activation and decrease viral load in early HIV. Scientific Ration...
Eligibility Criteria
Inclusion
- HIV-1 infected adults
- CD4 count \> 250 cells/mm3
- Not presently receiving HIV antiretroviral therapy (\> 6 months or naïve)
- Viral load \> 3000 RNA copies/mL (3.5 log)
- No planned HIV anti-retroviral therapy for 8 weeks
Exclusion
- Prior retinal eye disease
- CD4 \< 250 cells/µL
- Renal failure
- Active malignancy
- Corticosteroid therapy
- Age \< 18 or \> 65 years
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT00308620
Start Date
March 1 2006
End Date
June 1 2009
Last Update
June 4 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Minnesota ACTU
Minneapolis, Minnesota, United States, 55455